The bacterium that causes the plague belongs to a virulent family of bacteria called Yersinia, a group that also includes a pathogen responsible for food poisoning. These bacteria insert into their host cells proteins and other virulence factors, which kill by — among other things — disrupting the cells’ normal structure. One of these proteins, called YpkA, attacks a cell’s internal skeleton. Now, a study published by Rockefeller University researchers in the most recent issue of Cell shows exactly how YpkA does this, proving the protein’s mechanism from the atomic to the organismal level and providing a potential target for new antibiotic drugs.
C. Erec Stebbins, associate professor and head of the Laboratory of Structural Microbiology, and graduate student Gerd Prehna solved the structure for one region of the YpkA protein, a “binding domain” where it interlocks with another protein on the host cell’s membrane. By looking at the crystal structure of this protein-protein complex, Prehna discovered that the configuration looked just like one formed by some of the host’s own signaling proteins. And it’s this mimicry, he found, that leads to a signaling shutdown and deregulation of the cell’s normal structure.
After establishing this effect, Prehna set about disrupting it by mutation. Using the structure to guide him, he changed three amino acids of YpkA that contacted host proteins, and then looked at how the mutated bacteria affected human cells compared to the original wild-type Yersinia. His results confirmed the hypothesis from the structural study: While the wild-type YpkA wreaked havoc on their host cells’ cytoskeletons, the mutant left the actin-based skeleton intact.
Then, the researchers took it one step further. Stebbins and Prehna worked with collaborators at Stony Brook University, who created Yersinia bacteria with Prehna’s mutations. The Stony Brook researchers then injected mice with the wild-type and mutant strains ofYersinia. All the mice infected with the wild-type bacteria died within nine days of exposure. But the group that received the YpkA mutant had an 80 percent survival rate, showing that Prehna’s mutation drastically loweredYersinia’s harmful effects. “Altering this binding site not only impairs the bacteria’s ability to disrupt the host cytoskeleton,” Stebbins says, “but it decreases its virulence significantly.”
“It’s rare to find something that has such a strong effect that you can hit one protein so specifically, knock out essentially half its activity, and have such a dramatic result,” he says. “Not only did we have a mechanistic explanation, but we could connect what we were seeing in animal studies all the way down to what was happening at the atomic level.”